Malignant neuroleptic syndrome in treatment with the new, atypical antipsychotic agents, risperidone and olanzapine
Gram, L.F.
Ugeskrift for Laeger 162(13): 1914-1915
2000
ISSN/ISBN: 0041-5782 PMID: 10765710 Document Number: 524990
Document emailed within 1 workday
Related Documents
Emborg, C. 1999: Neuroleptic malignant syndrome after treatment with olanzapine Ugeskrift for Laeger 161(10): 1424-1425Gleason, P.P.; Conigliaro, R.L. 1997: Neuroleptic malignant syndrome with risperidone PharmacoTherapy 17(3): 617-621
Moltz, D.A.; Coeytaux, R.R. 1998: Case report: possible neuroleptic malignant syndrome associated with olanzapine Journal of Clinical Psychopharmacology 18(6): 485-486
Mishra, B.; Mishra, B.; Sahoo, S.; Arora, M.; Khess, C.R.J. 2007: Atypicality in presentation of neuroleptic malignant syndrome caused by olanzapine Indian Journal of Medical Sciences 61(10): 570-573
Lavie, C.J.; Olmsted, T.R.; Ventura, H.O.; Lepler, B.J. 1986: Neuroleptic malignant syndrome. An underdiagnosed reaction to neuroleptic agents? Postgraduate Medicine 80(3): 171-178
Nightengale, B.S.; Crumly, J.M.; Liao, J.; Lawrence, B.J.; Jacobs, E.W. 1998: Economic outcomes of antipsychotic agents in a Medicaid population: traditional agents vs. risperidone Psychopharmacology Bulletin 34(3): 373-382
Borison, R.L. 1996: Changing antipsychotic medication: guidelines on the transition to treatment with risperidone. The Consensus Study Group on Risperidone Dosing Clinical Therapeutics 18(4): 592-607; discussion 591
Gosselin, O.; Di Scala, G.; Ribeyre, J.M.; Kahn, J.P. 1996: New antipsychotic agents: new paths of research on the notion of atypical agents L'Encephale 22(Special Issue 6): 3-6
Omori, T. 2001: Efficacy of atypical antipsychotic agents for maintenance therapy of schizophrenia Seishin Shinkeigaku Zasshi 103(6): 470-475
Roth, B.L.; Ciaranello, R.D.; Meltzer, H.Y. 1992: Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors Journal of Pharmacology and Experimental Therapeutics 260(3): 1361-1365
Leikin, J.B.; Baron, S.; Engle, J.; Zell, M.; Hryhorczuk, D.O. 1988: Treatment of neuroleptic malignant syndrome with diphenhydramine Veterinary and Human Toxicology 30(1): 58-59
Sakkas, P.; Davis, J.M.; Janicak, P.G.; Wang, Z.Y. 1991: Drug treatment of the neuroleptic malignant syndrome Psychopharmacology Bulletin 27(3): 381-384
Guerrero, R.M.; Shifrar, K.A. 1988: Diagnosis and treatment of neuroleptic malignant syndrome Clinical Pharmacy 7(9): 697-701
Kongsakon, R.; Leelahanaj, T.; Price, N.; Birinyi-Strachan, L.; Davey, P. 2005: Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol Journal of the Medical Association of Thailand 88(9): 1267-1277
Iqbal, S.P.; Khan, R.A.M.; Ahmer, S. 2011: Antipsychotic treatment and weight gain: does risperidone behave differently in Pakistani psychiatric patients? Journal of Ayub Medical College Abbottabad: Jamc 23(1): 66-69
Mueller, P.S.; Vester, J.W.; Fermaglich, J. 1983: Neuroleptic malignant syndrome. Successful treatment with bromocriptine JAMA 249(3): 386-388
Blümlein, G. 1997: Successful use of amantadine in treatment of malignant neuroleptic syndrome Psychiatrische Praxis 24(5): 257-258
Lee, D.W.; Fowler, R.B. 2003: Olanzapine/risperidone and diabetes risk Journal of Clinical Psychiatry 64(7): 847-8; Author Reply 848
Roth, B.L.; Craigo, S.C.; Choudhary, M.S.; Uluer, A.; Monsma, F.J.; Shen, Y.; Meltzer, H.Y.; Sibley, D.R. 1994: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors Journal of Pharmacology and Experimental Therapeutics 268(3): 1403-1410
Kim, K.; Aas, E. 2011: Cost-effectiveness analysis of olanzapine and risperidone in Norway Journal of Mental Health Policy and Economics 14(3): 125-135